KalVista Pharmaceuticals Inc [KALV] stock is trading at $12.00, up 2.17%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KALV shares have gain 13.85% over the last week, with a monthly amount drifted -0.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
KalVista Pharmaceuticals Inc [NASDAQ: KALV] stock has seen the most recent analyst activity on January 31, 2025, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $19. Previously, TD Cowen started tracking the stock with Buy rating on January 07, 2025, and set its price target to $30. On December 18, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $22 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $30 on June 15, 2020. SVB Leerink initiated its recommendation with a Outperform and recommended $31 as its price target on July 29, 2019. Needham started tracking with a Buy rating for this stock on March 20, 2019, and assigned it a price target of $35. In a note dated October 30, 2018, Jefferies initiated an Buy rating and provided a target price of $30 on this stock.
KalVista Pharmaceuticals Inc [KALV] stock has fluctuated between $7.30 and $15.50 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. KalVista Pharmaceuticals Inc [NASDAQ: KALV] shares were valued at $12.00 at the most recent close of the market. An investor can expect a potential return of 133.33% based on the average KALV price forecast.
Analyzing the KALV fundamentals
Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at -150.43%, Pretax Profit Margin comes in at -142.31%, and Net Profit Margin reading is -145.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -1.07 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.76 points at the first support level, and at 11.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.20, and for the 2nd resistance point, it is at 12.41.
Ratios To Look Out For
For context, KalVista Pharmaceuticals Inc’s Current Ratio is 10.44. As well, the Quick Ratio is 10.44, while the Cash Ratio is 6.53.
Transactions by insiders
Recent insider trading involved Venrock Healthcare Capital Par, 10% Owner, that happened on Apr 09 ’25 when 25000.0 shares were purchased. CHIEF EXECUTIVE OFFICER, Palleiko Benjamin L completed a deal on Mar 07 ’25 to sell 6669.0 shares. Meanwhile, CHIEF MEDICAL OFFICER Audhya Paul K. sold 2394.0 shares on Feb 24 ’25.
